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Abstract Head and neck squamous cell carcinoma
(HNSCC) is a heterogeneous group of malignant tumours
that affects over 500,000 patients per year. Treatment
failure is generally due to the heterogeneity of these
tumours and to the serious adverse effects associated with
treatment. Immunological system impairment, which is
common in HNSCC, further contributes to treatment fail-
ure by mediating tumour escape mechanisms. To date, the
only clinically approved targeted therapy agent is cetux-
imab, a monoclonal antibody (mAb) that binds to, and
inhibits, epidermal growth factor receptor, which is widely
overexpressed in HNSCC. Cetuximab has been proven to
induce antibody-dependent cellular cytotoxicity, further
magnifying its therapeutic effect. DNA sequencing of
HNSCC cells has identified the presence of mutated genes,
thus making their protein products potential targets for
therapeutic inhibition. Immune mechanisms have been
found to have a significant impact on carcinogenesis, thus
providing the rationale to support efforts to identify anti-
cancer compounds with immunomodulatory properties. In
the context of the rapid development of novel targeted
agents, the aim of the present paper is to review our current
understanding of HNSCC and to review the novel
anticancer agents (mAbs and TKIs) introduced in recent
years, including an assessment of their efficacy and
mechanisms of action.
Keywords Head and neck cancer  mAb  TKI  Therapy
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the
sixth most common neoplasm worldwide, comprising a
heterogeneous group of malignancies arising from the
mucosal surfaces of the paranasal sinuses, the oral and
nasal cavities, the pharynx, and the larynx [1]. Although
our understanding of these tumours has improved signifi-
cantly in recent years, treatment outcomes have barely
improved [2]. The three most commonly reported risk
factors for HNSCC are alcohol, tobacco, and human
papilloma virus (HPV) infection [2]. Tobacco smoke has
over 5000 chemicals, with at least 60 proven to be cyto-
toxic, mutagenic, and carcinogenic, which explains the
important impact of tobacco on the incidence of HNSCC
[3]. Tobacco smoke also increases the level of reactive
oxygen species (ROS), which in turn stimulate expression
of interleukin 8 (IL-8), a pro-inflammatory cytokine,
leading to prolonged inflammation [4].
The most common treatments for head and neck cancer
include surgery, radiation, and chemotherapy (CT), or a
combination thereof. Currently, six agents have received
Food and Drug Administration (FDA) approval for the
treatment of HNSCC: cisplatin, 5-fluorouracil, docetaxel,
methotrexate, bleomycin, and cetuximab, a monoclonal
antibody (mAb). Platinum-based chemotherapy agents
such as carboplatin and cisplatin, with an efficacy of up to
40%, are standard treatments for HNSCC, often used in
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combination with ionizing radiation [5]. Their mechanism
of action is related to the formation of covalent bonds with
nucleic acids. Docetaxel, which was approved by FDA in
2006 for use in locally advanced inoperable tumours, is a
taxane that promotes cell cycle arrest and apoptosis [6].
Cisplatin is often used to treat non-resectable malignancies,
metastatic lesions, and as a complementary chemotherapy
agent. However, an important disadvantage of cytostatic
agents is their lack of selectivity in targeting cells.
Tumours are more susceptible to CT only because of their
higher rate of division compared to healthy cells [6], which
explains why CT is associated with high cytotoxicity and
serious adverse effects including neutropenia, alopecia,
stomatitis, and mucositis. These adverse effects are rele-
vant because they can significantly decrease overall quality
of life [7].
To date, cetuximab remains the only targeted agent for
the treatment of HNSCC. Cetuximab was first proposed for
use in HNSCC after it was discovered that epidermal
growth factor receptor (EGFR) was significantly overex-
pressed in HNSCC and this overexpression is associated
with worse prognosis [8] and greater radioresistance [9].
HNSCC tumours also significantly increase immunosup-
pression in patients, as evidenced by decreased absolute
lymphocyte counts compared to healthy individuals [10].
Elevated levels of inflammatory cytokines (IL-6, TGF-b,
VEGF, HGF) at the tumour site enhance cellular prolifer-
ation and migration [11, 12] and also increase the risk of
relapse and metastasis [13]. Other characteristics observed
in immunosuppressive HNSCC include impaired antigen-
presenting functions [14], aberrant natural killer (NK) cell
activity [15], and increased apoptosis of CD8? cells [16].
In addition, dysregulation of antigen-presenting mecha-
nisms is also typically present in HNSCC [14] and the
impact of a dysregulated cytokine profile is crucial because
tumours tend to favour immunosuppressive and pro-in-
flammatory cytokines rather than stimulatory cytokines, an
imbalance that contributes to tumour immune escape
mechanisms [11].
Given the rapid development of new agents with ther-
apeutic potential for HNSCC, the aim of this paper is to
review our current understanding of HNSCC and to assess
the efficacy and mechanisms of action of the novel anti-
cancer agents introduced in recent years.
mAbs-based immunotherapy
Molecular heterogeneity in HNSCC significantly lowers
the chance of identifying a single therapeutic agent that is
effective for all HNSCC tumour types. However,
sequencing analysis of HNSCC tumours has provided data
to help identify numerous new potential therapeutic targets
that are overexpressed in these carcinomas and believed to
contribute to tumourigenesis [17, 18]. Such targets include
the following: EGFR, vascular endothelial growth factor
(VEGF), programmed cell death protein (PD-1), hepato-
cyte growth factor (HGF), phosphatidylinositol-4,5-bis-
phosphate 3-kinase (PI3K), c-Met pathway elements,
cytotoxic T lymphocyte-associated protein 4 (CTLA-4),
and CD137.
Cetuximab is a monoclonal chimeric antibody with the
ability to bind to EGFR, a cell surface receptor of the
EGFR tyrosine kinase inhibitor (TKI) family. The four
other members of this family include EGFR1, HER2,
HER3, and HER4 [4, 19]. Activated EGFR homo- or
heterodimerizes along with other receptors result in phos-
phorylation of tyrosine and subsequent activation of sig-
nalling pathways such as MAPK, PI3K/Akt, or STAT.
Induction of these pathways may result in dysregulation of
apoptosis, proliferation, and transcription [11, 20].
Apart from targeting EGFR, cetuximab also stimulates
the induction of antibody-dependent cellular cytotoxicity
(ADCC). Recent studies have found that ADCC can be
further enhanced by activating CD137, a co-stimulatory
molecule overexpressed by NK and T cells after stimula-
tion. CD137 expression in NK cells is triggered by expo-
sure to cetuximab, thus increasing ADCC [21]. Based on
this effect, it has been postulated that an additional appli-
cation of CD137 agonists after cetuximab-based therapy
might improve treatment response [22].
Kohrt et al. reported that cetuximab response is highly
dependent on CD8? cells. Enhancement of cetuximab
response is mediated by dendritic cell maturation, induced
by NK cells [23]. Furthermore, stimulation of peripheral
blood cells through TLR 8? (Toll-like receptor 8) further
augments cetuximab-induced ADCC and promotes den-
dritic cell maturation in HNSCC [24].
However, HNSCC tumours can develop resistance to
cetuximab. The mechanism behind this resistance process
is signalling based, leading to activation of the other
members of the EGFR family: HER2, HER3, as well as
c-Met and insulin growth factor receptor (IGFR) [4, 19].
Another aim of therapeutic inhibition is activation of the
c-Met/HGF signalling pathway, which is recognized as a
major contributing factor to HNSCC resistance to EGFR,
cisplatin, and radiation [25]. Antibodies targeting those
pathways are under clinical evaluation and currently
include transtuzumab, pertuzumab, onartuzumab, and cix-
utumumab [26, 27]. HGF also contributes to the inhibition
of dendritic cell (DC) maturation. Anti-HGF mAb (AMG-
102, rilotumumab) has been developed to eliminate this
effect, and AMG-102 is currently undergoing evaluation in
the treatment of renal cell carcinoma (RCC) [28], advanced
solid tumours, and metastatic gastric esophagogastric
adenocarcinoma [29]. Activation of c-Met can be blocked
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by ficlatuzumab, a humanized anti-HGF mAb currently
being tested in combination with cetuximab in HNSCC
[30]. Increased expression of c-Met correlates with resis-
tance to platinum-based agents, radiation, and to EGFR-
targeting agents; given that most HNSCC samples over-
express c-Met, this may be a novel therapeutic target [31].
Hayakawa et al. [32] found that IL-6 levels were
upregulated in HNSCC, and elevated levels of IL-6 are
associated with STAT3 signalling and blockage of DC
maturation, which makes them a potential target for ther-
apeutic inhibition. Siltuximab, a chimeric monoclonal
antibody directed against IL-6, was designed to restore
physiological STAT3 signalling and DC maturation. The
efficacy of siltuximab in the treatment of metastatic pros-
tate cancer is under evaluation [33].
Another EGFR-targeting antibody is zalutumumab [34].
This human IgG1 mAb is characterized by high affinity to
EGFR and low immunogenicity. The main advantage of
zalutumumab is its immunogenicity, which, while
improving overall tolerance, does not impair ADCC
induction [35]. The efficacy of zalutumumab has been
evaluated in incurable HNSCC, where it increased overall
survival by 1.5 months versus healthy controls [36]. Pan-
itumumab, another anti-EGFR molecule, is a human IgG2
mAb with less capacity to enhance ADCC compared to
cetuximab. Panitumumab, which has a reduced affinity for
the CD16 receptor, has been shown to present fewer
hypersensitivity reactions. Panitumumab has been evalu-
ated in combination with cisplatin and 5-FU in HNSCC,
yielding a greater than threefold decrease in disease pro-
gression when compared to CT alone; however, this com-
bined treatment was also associated with a significant
increase in serious adverse effects [37]. The efficacy of
panitumumab in monotherapy [38] is currently being
evaluated [20]. Nimotuzumab is a recombinant humanized
murine antibody targeting EGFR. The activity of nimo-
tuzumab as a complement to standard chemotherapy has
been evaluated in locally advanced HNSCC [39]; assess-
ment of its efficacy combined with CRT is ongoing [40].
MEHD7945A is another anticancer mAb whose main
advantage is an affinity for both EGFR and HER3 [41].
MEHD7945A may act as a radiation sensitizer in both lung
cancer and HNSCC. Studies conducted to date have shown
that this drug can effectively enhance radiation response in
those neoplasms, both in vitro and in vivo [41].
Angiogenesis is crucial to tumour proliferation, inva-
sion, and metastasis. The process is enhanced by low
oxygen levels and VEGF overexpression [42]. Considering
the importance of VEGF in inducing vascularization, ele-
vated levels of VEGF (both the growth factor and its
receptors) correlate with poor prognosis [24], which
explains the interest in bevacizumab, a VEGF-targeted
mAb. The main advantage of bevacizumab is its affinity for
all five VEGF isophorms [43]. However, studies that have
investigated bevacizumab as monotherapy have found no
significant change in response or overall survival [44]. By
contrast, when it is added as a complementary treatment to
standard, platinum-based CT, it substantially improves the
outcomes of patients with advanced non-small cell lung
carcinoma (NSCLC) [43]. This raises the possibility that
bevacizumab could have a similar effect in HNSCC [44]. A
trial of bevacizumab with CT in locally advanced HNSCC
is currently ongoing [45].
The clinical use of mAbs such as cetuximab and tras-
tuzumab (which targets EGFR and HER2), designed to
inhibit signalling promoting cell proliferation and evasion
of apoptosis, yields a better overall response than TKIs
targeting the same molecules [11]. Those findings suggest
that some other immune mechanisms, apart from blockage
of downstream signalling, must contribute to the clinical
success of these agents [11]. In xenograft models
expressing HER2, trastuzumab and pertuzumab induced
ADCC [46], leading the authors to suggest that co-targeting
tumour antigens (TA) with mAbs might further enhance
immune response.
The loss of phosphatase and tensin homologue (PTEN)
and transforming growth factor b receptor 1 (TGF-bR1) are
associated with PD-L1 activation, possibly through the Akt
signalling pathway [47, 48]. Studies have found PD-1
overexpression in 68–70% of HNSCC malignancies [26],
regardless of HPV infection status [49, 50]. PD-1 is a
receptor present on the surface of cytotoxic T lymphocytes
(CTLs), B and NK cells, and macrophages. PD-1 is
expected to be superior to CTLA-4 in negative signalling.
PD-L1 and PD-L2 are ligands of PD-1. After prolonged
exposure to antigens, macrophages and dendritic cells start
to overexpress PD-L1, which, in the HNSCC setting, leads
to decreased CTL and NK cell activity [51]. If antigen
stimulation continues, CTLA-4 and PD-1 receptors down-
regulate CTL response, thus resolving post-infectious
inflammation and thwarting the autoimmune response.
Those ‘‘immune checkpoints’’ serve a useful purpose in
cancers; however, they may lead to pathologic tolerance
and thus contribute to tumour immune escape [48]. A
humanized IgG4 anti-PD-1 mAb (nivolumab) has been
developed to release CTLs and NK cells from anergy, and
this drug has been evaluated in renal carcinoma, mela-
noma, and NSCLC. The evaluation of nivolumab in
HNSCC is ongoing [52]. Pembrolizumab, an anti-PD1
mAb, is currently in phase 2 clinical trial in patients with
metastatic HNSCC after standard platinum-based therapy
[53]. Durvalumab also targets PD-L1, however is less
effective than pembrolizumab, and evokes approximately
11% response [54].
The development of agents to reduce co-inhibitory sig-
nalling and activate CTLs is a recent aim of HNSCC
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treatment and ipilimumab is one of the agents that is
potentially capable of achieving this effect. This anti-
CTLA-4 IgG1 mAb is currently used to treat melanoma
[55]. A decrease in co-inhibitory CTLA-4 signalling leads
to amplification of tumour-specific CTLs, thus having a
therapeutic effect [56]. However, such agents should be
administered with caution since they have been reported to
cause severe adverse effects such as hypopituitarism or
colitis [57]. Another agent with a similar mechanism in
current trials is tremelimumab [58].
mAbs targeting PD-1 and PDL-1 have shown a signifi-
cant response in solid tumours such as melanoma, renal
cell carcinoma, and NSCLC [11]. Recent studies indicate
that application of anti-PD-1 mAb in HNSCC significantly
inhibits proliferation and decreases levels of myeloid-
derived suppressor cells (MDSCs) and tumour-associated
macrophages (TAMs), while elevating CD8? cell popula-
tion levels [49]. Nivolumab, an anti-PD-1 mAb, has been
shown to have lower toxicity than CTLA-4-targeted anti-
bodies; moreover, the adverse effects associated with
therapy tend to be less severe and include fatigue and
pyrexia [46]. Currently, nivolumab is in phase III trial in
metastatic HNSCC [59].
OX40 (a tumour necrosis factor receptor) is a compo-
nent of the co-stimulatory pathway, which can strengthen T
cell memory and anti-tumour activity, thus reducing cancer
immune escape mechanisms [60]. Main reason to use
OX40 is that it has a proven co-expression with PD-1 and
CTLA-4 [48]. Antibodies targeting OX40 might increase T
cell signalling and enhance the proliferation of these T
cells, memory, and cytotoxicity. Several studies have found
that OX40-targeting mAbs may have synergistic effects
when administered with other immunotherapeutics [61].
Guo et al. have shown that the combination of anti-OX40
mAb and anti-PD-1 improves overall survival compared to
any of these agents alone [62, 63].
Tyrosine kinase inhibitors (TKIs)
Another group of agents that has emerged recently are
TKIs. These are a class of chemotherapeutics that block
specific tyrosine kinases involved in pathways essential for
tumour growth, invasion, and metastasis. By binding to the
tyrosine kinase domain of EGFR, TKIs block subsequent
signalling, resulting in inhibition of cell proliferation [62].
Two most commonly used TKIs are gefitinib and erlo-
tinib. Gefitinib, which targets EGFR, causes reversible
inhibition of the receptor; this TKI has been tested in
conjunction with standard CT or CRT in HNSCC, and in
2015, it was approved by the FDA for monotherapy
treatment of NSCLC. Erlotinib is another EGFR kinase
inhibitor whose efficacy has been proven in over 80 clinical
trials. It is currently approved for NSCLC and pancreatic
cancer. Although trials have shown that erlotinib yields
good results when added to radiotherapy, its use in com-
bination with cisplatin is not recommended. A phase III
clinical trial of erlotinib–cisplatin–radiation efficacy is
ongoing [64].
Since heterodimerization of EGFR with other receptors
is suspected to limit the benefits of mAbs and TKIs, it has
been suggested that agents that can simultaneously inhibit
several members of the EGFR family could be useful [62].
This explains the growing interest in small molecule inhi-
bitors—such as lapatinib, afatinib, sorafenib, and suni-
tinib—that target multiple receptors. Lapatinib is a
reversible TKI, directed against both EGFR and HER2
kinases. Afatinib, through covalent bond formation, irre-
versibly blocks EGFR, HER2, and HER4 kinases. One trial
showed that co-administration of afatinib with cetuximab
in HNSCC significantly reduced cell viability, suggesting
an additive or synergistic effect [65]. The efficacy of
sunitinib and sorafenib is due to inhibition of VEGFR,
PDGFR, Flt3, and c-kit.
The hallmark of HNSCC tumour cells is an imbalance in
STAT1/STAT3 signalling. While downregulation of the
STAT1 signalling pathway decreases the concentration of
CCL5 and CXCL10 (cytokines that promote T cell
migration), upregulation of STAT3 increases cytokine
secretion. IL-6, IL-10, TGF-b1, and VEGF contribute to
impaired DC maturation and NK cell-mediated cytolysis
[66]. The function of IFN-c is to enhance HLA and antigen
presentation in tumour and dendritic cells. This process is
downregulated in the tumour environment due to lack of
IFNc-induced STAT1 signalling. Moreover, DC matura-
tion is inhibited by the downregulation of the STAT3
pathway mediated by secretion of IL-6 by tumour cells.
The therapeutic aim is to restore the balance between the
STAT1/STAT3 pathways, either by inhibiting enhanced
STAT3 or by inducing suppressed STAT1. In vitro studies
have shown that downregulation of STAT3 signalling
reduces the immunosuppressive characteristics of HNSCC
[67]. An anti-Src TKI (dasatinib) may be useful due to
STAT3 mediation execution. Two clinical trials have
evaluated the efficacy of dasatinib in combination with
cetuximab and CT [68, 69].
The use of Janus kinases offers another approach to
reverse the STAT1/STAT3 imbalance. STAT3 is activated
after interaction with JAK1, and JAK2 and Src. JAK1 and
JAK2 are phosphorylated through IL-6-mediated stimula-
tion. For this reason, researchers have recently sought to
develop agents to downregulate STAT3 by targeting JAK
receptors. Research in this area has led to the development
of the novel drug ruxolitinib. JAK1 and JAK2 inhibitors
have been approved for the treatment of myeloproliferative
neoplasms [70]. A second JAK1 and JAK2 inhibitor—
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Table 1 Compilation of the novel targeted therapy agents in HNSCC treatment
Drug Mechanism Target Phase Status Sponsor References
Cetuximab mAb EGFR FDA
approved
ImClone Systems, Inc.
Panitumumab EGFR II Ongoing Amgen [38]
Nimotuzumab EGFR II Ongoing National Cancer Centre [40]
Zalutumumab EGFR III Completed Genmab [36]
MEDH7945A EGFR, HER3 II Completed Genentech [74]
Transtuzumab HER2 II Unknown Bristol-Myers Squibb, Genentech [75]
AV-203 HER3 I Completed AVEO Pharmaceuticals, Inc. [76]
Cixutumumab IGFR II Completed ImClone LLC [77]
Bevacizumab VEGF II Ongoing Woondong Jeong [45]
Pembrolizumab PD-1 II Ongoing Merck Sharp and Dohme Corp [53]
Nivolumab PD-1 III Ongoing Bristol-Myers Squibb [59]
Durvalumab PD-L1 II Recruiting AstraZeneca [54]
Onartuzumab c-Met II Completed Genentech, Inc. [78]
Rilotumumab HGF II Completed Amgen [28]
Ficlatuzumab HGF I Recruiting Julie E. Bauman, MD, MPH [30]
Siltuximab IL-6 II Completed Southwest Oncology Group [33]
Ipilimumab CTLA-4 I Recruiting National Cancer Institute [79]
Tremelimumab CTLA-4 III Recruiting AstraZeneca [58]
Urelumab CD137 I Ongoing Bristol-Myers Squibb [80]
Gefitinib TKI EGFR II Completed AstraZeneca [81]
Erlotinib EGFR III Ongoing Grupo de Investigacio´n Clı´nica en
Oncologı´a Radioterapia
[64]
Dacomitinib EGFR I,II Completed University Health Network [82]
Lapatinib EGFR, HER2 III Completed GlaxoSmithKline [83]
Afatinib EGFR, HER2,
HER4
III Recruiting Centre Leon Berard [84]
Sunitinib VEGFR, PDGFR,
Flt3, c-kit
I Terminated National Cancer Institute [85]
AZD-1480 JAK1, 2 I Terminated AstraZeneca [86]
Ruxolitinib JAK1, 2 0 Not yet
recruiting
University of Pittsburgh [87]
Tivantinib c-Met II Ongoing National Cancer Institute [88]
Foretinib VEGFR, c-Met II Completed GlaxoSmithKline [89]
Sorafenib VEGFR, PDGFR,
Raf
I, II Completed Duke University [90]
Dasatinib Src I, II Ongoing Sidney Kimmel Comprehensive Cancer
Center
[69]
GDC-0941 PI3K I Completed Genentech, Inc. [91]
PX-866 PI3 K I, II Completed Oncothyreon Inc. [92]
NVP-BKM120 PI3K II Ongoing Novartis Pharmaceuticals [93]
PVP BYL719 PI3K II Recruiting Novartis Pharmaceuticals [94]
Everolimus mTOR I Not yet open M.D. Anderson Cancer Center [95]
IL-2 Immunomodulators II Completed H. Lee Moffitt Cancer Center and Research
Institute
[96]
IL-12 I, II Ongoing National Cancer Institute [97]
IFN-a2a III Completed Eastern Cooperative Oncology Group [98]
Bortezomib Proteasome II Completed Vanderbilt-Ingram Cancer Center [99]
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AZD1480—has been tested both in vitro and in vivo, with
findings showing that AZD1480 effectively decreases IL-6-
mediated STAT3 activation, thus inhibiting cell prolifera-
tion and inducing apoptosis. In mice, administration of
AZD1480 has been reported to increase overall survival
[71].
PI3Ks (phosphatidylinositide 3-kinases) are a family of
enzymes engaged in various cellular processes such as
proliferation, differentiation, and motility, which are rela-
ted to tumourigenesis. The PIK3A gene is often mutated in
HNSCC, making the pathway an attractive target for
therapeutic inhibition. Furthermore, mutations in PIK3A
elements are responsible for the subsequent activation of
the Akt and mTOR pathways. To date, several small
molecule inhibitors of PI3K have been developed, includ-
ing GDC-0941, PX-866, NVP-BKM120, and
NVPBYL719.
NK cells are one of the most important components of
innate immunity, and these large cytotoxic lymphocytes
are the main drivers of ADCC execution [72]. However,
their activity in HNSCC may be impaired due to down-
regulation of the NK cell receptor (NKG2D). NKG2D
depletion is promoted by increased TGF-b levels [51]. For
this reason, it has been suggested that immunotherapy
could improve response provided that expression of TGF-b
concentrations at the tumour site can be decreased; one
approach to reducing TGF-b expression is through c-Met
blockage, which lowers the production of TGF-b, thus
sensitizing tumour cells to immune mechanisms. Kumai
et al. have shown that tivantinib, a TKI targeting c-Met,
leads to a significant decrease in TGF-b production, thus
resulting in better response and improved immune mech-
anisms. Collectively, previous studies have found a critical
role for the c-Met/HGF pathway in cancer proliferation and
metastasis, indicating that the c-Met/HGF may be a viable
target for future therapy development [73]. Table 1 shows
a compilation of the novel targeted therapy agents that may
be useful in HNSCC treatment.
Conclusions
Immune response is crucial in most cancers, particularly in
HNSCC, because the tumour response may contribute to
tumour evasion mechanisms, resistance to therapeutic
agents, and disease progression. At present, the main aim
of immunotherapy in HNSCC is to magnify the immune
response, such as ADCC, and to sensitize cells to con-
ventional treatments. Compared to standard treatments, the
main advantage of immunotherapy is its distinctly higher
specificity, which implies less cytotoxicity and better
overall tolerance. The immunosuppressive characteristics
of HNSCC stem from elevated levels of inflammatory
cytokines in the tumour microenvironment. This, apart
from mediating cellular proliferation and migration, also
contributes to higher relapse rates and metastasis. There-
fore, restoring balance to the cytokine profile could yield
treatment benefits. The search for novel agents will
undoubtedly continue, and it is essential that we determine
the most effective combinations of known therapeutic
compounds in order to improve treatment outcomes in
HNSCC.
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